文献速递区域麻醉与超声疼痛医学

椎间突阻滞对乳腺癌大手术影响不显著:随机盲法安慰剂对照临床试验

Insignificant influence of the intertransverse process block for major breast cancer surgery: a randomized, blinded, placebo-controlled, clinical trial.
PubMed 文献 · Reg Anesth Pain Med · 2024-01-11

该随机、盲法、安慰剂对照临床试验纳入36例拟行单侧胸肌下假体植入乳房重建的乳腺癌患者,比较单侧多点注射椎间突阻滞(0.5%罗哌卡因3×10 mL)与安慰剂阻滞(生理盐水3×10 mL)在T2、T4、T6的效应。主要结局为术后24小时内阿片类药物总消耗量,结果显示活性组与安慰剂组中位数(IQR)分别为75.0 mg(45-135)和62.5 mg(30-115),p=0.5,无显著差异;次要结局亦无临床相关阳性结果。结论认为术前多点注射椎间突阻滞既不减少术后24小时阿片消耗,也未带来实质性临床获益。

要点

  • 乳腺癌大重建手术中,术前多点注射椎间突阻滞未减少术后24小时阿片消耗。
  • 活性组与安慰剂组24小时阿片消耗中位数分别为75.0 mg和62.5 mg,p=0.5。
  • 次要结局包括疼痛评分、满意度、首次阿片时间等均无临床相关差异。

核心结论

  • 乳腺癌大重建手术后,术前多点注射椎间突阻滞既不减少术后24小时阿片消耗,也未促进实质性临床阳性结局。

研究设计与样本

  • 前瞻性、随机、盲法、安慰剂对照临床试验,筛查58例,随机分配36例乳腺癌患者。
  • 患者接受单侧胸肌下假体植入原发性乳房重建,包括乳房切除术及胸大肌筋膜完全剥离。
  • 活性组接受单侧多点注射椎间突阻滞(0.5%罗哌卡因3×10 mL),安慰剂组接受生理盐水3×10 mL,注射点为T2、T4、T6。
  • 主要结局为术后首个24小时内阿片类药物总消耗量。

主要发现

  • 术后24小时内阿片消耗量活性组与安慰剂组中位数(IQR)分别为75.0 mg(45-135)和62.5 mg(30-115),p=0.5,无显著差异。
  • 次要结局包括每4小时阿片消耗、术后疼痛、患者对阻滞应用的满意度、首次阿片时间、下床活动与出院时间、阿片相关副作用及恢复质量,均未发现 consequential 临床相关结果。

临床怎么用

  • 对于乳腺癌大重建手术,不应常规期望术前多点注射椎间突阻滞能减少术后阿片消耗或改善临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The intertransverse process (ITP) block mimics the thoracic paravertebral block and allegedly ameliorates hemithoracic postoperative pain. However, concerning major reconstructive breast cancer surgery the modality has never been tested against placebo in a randomized clinical trial. We aimed to assess the efficacy of the multiple-injection ITP block and hypothesized that the blockade would reduce postoperative opioid consumption. METHODS: We screened 58 patients with breast cancer scheduled for unilateral subpectoral implant-based primary breast reconstruction, involving mastectomy with complete fascial dissection of the major pectoral muscle. A randomization procedure allowed for the allocation of 36 patients to receive either unilateral multiple-injection active ITP block (0.5% ropivacaine 3×10 mL) or placebo ITP block (isotonic saline 3×10 mL) at T2, T4, T6 in a prospective, blinded, clinical trial. The primary outcome was total opioid consumption within the first 24 postoperative hours. Secondary outcomes included opioid consumption at 4-hour intervals, postoperative pain, patient satisfaction with block application, time to first opioid, ambulation and discharge, opioid-related side effects, and quality of recovery. RESULTS: Opioid consumption within the first 24 postoperative hours showed no significant reduction when comparing the active and placebo group median (IQR): 75.0 mg (45-135) vs 62.5 mg (30-115), p=0.5, respectively. We did not find any consequential clinically relevant results of the secondary outcomes. CONCLUSIONS: Following major reconstructive breast cancer surgery, a preoperative multiple-injection ITP block neither reduces 24-hour opioid consumption postoperatively nor promotes substantial clinical positive outcomes. TRIAL REGISTRATION NUMBER: EudraCT2019-001016-35.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Nielsen MV, Tanggaard K, Hansen LB, et al. Insignificant influence of the intertransverse process block for major breast cancer surgery: a randomized, blinded, placebo-controlled, clinical trial. Reg Anesth Pain Med. 2024. PMID: 37169487. doi:10.1136/rapm-2023-104479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。